Open Accessibility Menu
  • Certified ALS Center Program
    Certified ALS Center Program
  • Level 4 Epilepsy Center - national association of epilepsy centers
    National Association of Epilepsy Centers
  • Comprehensive Stroke Center
  • AANEM EDX Lab Accreditation - exemplary status
    AANEM EDX Lab Accreditation

Headache Center

Treatment for All Types of Headache Disorders

The GW Medical Faculty Associates Headache Center was established in July 2015 with the mission to provide the Washington, D.C. area with expert headache services. We treat patients with all types of headache disorders, using a multi-faceted and personalized approach. In addition, we engage in research to advance the understanding of headaches and develop new/improved treatments.

To learn more about our mission and approach to headache management, please see our Mission Statement.

Meet Our Providers:

New Patients

Welcome to The GW Medical Faculty Associates Headache Center! We are excited to work with you to (1) diagnose your underlying headache disorder(s), (2) understand the impact your headaches have on your daily life and (3) develop an individualized treatment plan to improve the frequency and severity of your headaches, thus limiting/eliminating disability. We are devoted to empowering our patients, by emphasizing their active role in the management of their headache disorder(s).

Headaches can be disabling and complex. We use a multidisciplinary approach to achieve the best results. This can include:

  • Patient education
  • Physical therapy
  • Biofeedback and relaxation techniques
  • Psychotherapy
  • Medications to manage pain
  • Procedures (Botox, nerve blocks) to manage pain
  • Access to new treatments via participation in research protocols
  • Access to acute IV migraine therapy in our Headache Rescue Room

To make your first visit as efficient as possible, please fill out and bring the Patient Questionnaire to your first visit. If you have a referral, please bring it with you to your appointment. We recommend arriving at least 15 minutes prior to your scheduled appointment so we can maximize the amount of time we spend with you during your visit.

We believe in a strong patient-provider alliance, where we work as a team to regain control over your headaches. We look forward to working with you to alleviate your pain and improve your quality of life.

Clinical Trials

  • Protocol H8H-MC-LAIJ, Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks
    The objective of this Phase 3 study is to evaluate the efficacy of lasmiditan 200 mg and 100 mg on migraine headache pain freedom compared to placebo.
  • ARISE: pAdsevonil in drug-ResIStant Epilepsy: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PADSEVONIL AS ADJUNCTIVE TREATMENT OF FOCAL-ONSET SEIZURES IN ADULT SUBJECTS WITH DRUG-RESISTANT EPILEPSY, PHASE 2
    The primary objectives of this study are to characterize the dose-response relationship with respect to efficacy of PSL administered concomitantly with up to 3 anti-epileptic drugs (AEDs) for treatment of observable focal-onset seizures in subjects with drug-resistant epilepsy and to evaluate the efficacy of the 4 selected dose regimens of PSL compared with placebo. The secondary objective is to assess the safety and tolerability of all doses of PSL in relation to placebo.
  • Efficacy and Safety of Eslicarbazepine Acetate as First Add-on to Levetiracetam or Lamotrigine Monotherapy or as Later Adjunctive Treatment for Subjects with Uncontrolled Partial-onset Seizures: A Multicenter, Open-label, Non-randomized Trial

    The primary objective of this phase 4 study is to evaluate the effectiveness of ESL administered once daily (QD) as the first adjunctive therapy to levetiracetam (LEV) or lamotrigine (LTG) or as a later adjunctive therapy in subjects with partial onset seizures (POS) over a 24-week maintenance period in a real-world setting.

  • A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Exploring the Efficacy, Safety, and Tolerability of Natalizumab (BG00002) as Adjunctive Therapy in Adult Subjects With Drug-Resistant Focal Epilepsy
    The primary efficacy objective of the study is to determine if adjunctive therapy of natalizumab 300 mg intravenous (IV) infusion every 4 weeks reduces the frequency of seizures in adult subjects with drug-resistant focal epilepsy.
  • Low frequency electrical stimulation of the fornix in Intractable Mesial Temporal Lobe Epilepsy (MTLE)
    To develop a protocol to evaluate the safety and tolerability of low frequency stimulation of the fornix in patients with MTLE.